Puma Biotechnology (PBYI) Insider Jay Moyes Sells $159K of Stock

On June 12, 2026, Jay Moyes sold 22,000 shares of Puma Biotechnology, Inc. (NasdaqGS: PBYI) in a planned transaction. The shares were sold at an average price of $7.22, amounting to a total value of $158,840.

Insider Buying and Selling at Puma Biotechnology, Inc.

Several insiders at Puma Biotechnology engaged in transactions on June 12, 2026. Jay Moyes sold 22,000 shares at $7.22, while Allison Dorval and Brian Stuglik each sold shares at $7.20. Adrian Senderowicz also sold 27,000 shares on the same day. These sales were part of planned transactions.

Other Institutional Activity in Puma Biotechnology

Among Puma Biotechnology's institutional investors, Acorn Capital Advisors, LLC maintained its position with 4,131,299 shares valued at approximately $26.4 million. BlackRock, Inc. reduced its stake by 43,636 shares, leaving it with 3,598,952 shares worth about $23 million. On the other hand, American Century Companies Inc increased its holdings by 266,209 shares, ending with 1,916,346 shares valued at roughly $12.2 million.

Puma Biotechnology, Inc. Stock Down 26.4%

Shares of Puma Biotechnology were trading at $7.33. The company has a market capitalization of $359.9 million and a P/E ratio of 14.73. Its 52-week range is between $3.03 and $7.90. The stock's 50-day moving average is $7.25, while the 200-day moving average stands at $6.09. Puma Biotechnology's current ratio is 2.38, with a quick ratio of 2.14 and a debt-to-equity ratio of 12.42.

Recent Earnings

Puma Biotechnology reported a revenue of $227.2 million, reflecting a slight decrease of 2.6% compared to the previous period. The company achieved a net margin of 10.7% and a return on equity of 21.6%. Its earnings per share stood at $0.48. The next earnings report is anticipated on August 6, 2026.

Analysts Set New Price Targets

HC Wainwright & Co. reiterated a 'buy' rating for Puma Biotechnology with a price target of $7. Meanwhile, TD Cowen maintained a 'hold' rating with a target of $4. Barclays continued its 'sell' rating with a target of $2. The consensus target price among analysts is $5, with one analyst providing an opinion.

About Puma Biotechnology

Puma Biotechnology, Inc. is a healthcare company based in Los Angeles, California, specializing in the development and commercialization of cancer treatment products. With a focus on enhancing cancer care, it offers NERLYNX, an oral medication for HER2-positive breast cancer, and develops other treatments like alisertib for various cancer types. The company operates through specialty pharmacy and distributor networks and collaborates with partners such as Pfizer Inc. Puma Biotechnology was founded in 2010 and is led by CEO Alan H. Auerbach.

Bottom Line

Jay Moyes' recent sale of Puma Biotechnology shares is part of a planned transaction, reflecting ongoing insider activity. Investors track these moves to gauge insider sentiment, though they don't necessarily indicate future performance. Puma Biotechnology remains a key player in the biotechnology sector, with analysts offering mixed views on its stock.